Compare Inovio Pharmaceuticals Inc (INO) vs Warner Music Group Corp (WMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Warner Music Group Corp — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Warner Music Group Corp trades at $28.06 (market cap $14.64B). The key difference: Warner Music Group Corp is far larger — about 164× Inovio Pharmaceuticals Inc's market cap, and Warner Music Group Corp pays a 2.71% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | WMG | |
|---|---|---|
Market Cap | $89.27M | $14.64B |
Sector | Health | Media |
52-Week High | $2.87 | $34.72 |
52-Week Low | $1.05 | $23.65 |
Enterprise Value | $60.28M | $18.84B |
Dividend Yield | — | 2.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Warner Music Group (WMG) trades at $28.08, down 0.88% on the day, with a bearish technical signal and mixed earnings history. Revenue growth is steady, reaching $6.71B in 2025, but net income margin has declined to 5.44%. Recent developments include a strategic renewal with NetEase Cloud Music and the acquisition of AI startup Sureel AI, enhancing IP monetization capabilities in the evolving music industry.
The stock offers a 44% upside to the consensus price target of $40.40, supported by strong analyst buy ratings (66.66%), but faces risks from competitive pressures and margin compression. Investors should weigh the high P/E ratio of 33.73 against growth initiatives and cash flow improvements projected for 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
